Literature DB >> 18385100

Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease.

Sandro Alves1, Etienne Régulier, Isabel Nascimento-Ferreira, Raymonde Hassig, Noelle Dufour, Arnulf Koeppen, Ana Luísa Carvalho, Sérgio Simões, Maria C Pedroso de Lima, Emmanuel Brouillet, Veronica Colomer Gould, Nicole Déglon, Luís Pereira de Almeida.   

Abstract

Machado-Joseph disease (MJD) is a fatal, dominant neurodegenerative disorder. MJD results from polyglutamine repeat expansion in the MJD-1 gene, conferring a toxic gain of function to the ataxin-3 protein. In this study, we aimed at overexpressing ataxin-3 in the rat brain using lentiviral vectors (LV), to generate an in vivo MJD genetic model and, to study the disorder in defined brain regions: substantia nigra, an area affected in MJD, cortex and striatum, regions not previously reported to be affected in MJD. LV encoding mutant or wild-type human ataxin-3 was injected in the brain of adult rats and the animals were tested for behavioral deficits and neuropathological abnormalities. Striatal pathology was confirmed in transgenic mice and human tissue. In substantia nigra, unilateral overexpression of mutant ataxin-3 led to: apomorphine-induced turning behavior; formation of ubiquitinated ataxin-3 aggregates; alpha-synuclein immunoreactivity; and loss of dopaminergic markers (TH and VMAT2). No neuropathological changes were observed upon wild-type ataxin-3 overexpression. Mutant ataxin-3 expression in striatum and cortex, resulted in accumulation of misfolded ataxin-3, and within striatum, loss of neuronal markers. Striatal pathology was confirmed by observation in MJD transgenic mice of ataxin-3 aggregates and substantial reduction of DARPP-32 immunoreactivity and, in human striata, by ataxin-3 inclusions, immunoreactive for ubiquitin and alpha-synuclein. This study demonstrates the use of LV encoding mutant ataxin-3 to produce a model of MJD and brings evidence of striatal pathology, suggesting that this region may contribute to dystonia and chorea observed in some MJD patients and may represent a target for therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18385100     DOI: 10.1093/hmg/ddn106

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  31 in total

Review 1.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

Review 2.  Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions.

Authors:  Jean-Luc Dreyer
Journal:  Mol Biotechnol       Date:  2011-02       Impact factor: 2.695

3.  Ubiquitin-binding site 2 of ataxin-3 prevents its proteasomal degradation by interacting with Rad23.

Authors:  Jessica R Blount; Wei-Ling Tsou; Gorica Ristic; Aaron A Burr; Michelle Ouyang; Holland Galante; K Matthew Scaglione; Sokol V Todi
Journal:  Nat Commun       Date:  2014-08-21       Impact factor: 14.919

4.  Adenosine A2A Receptors in the Amygdala Control Synaptic Plasticity and Contextual Fear Memory.

Authors:  Ana Patrícia Simões; Nuno J Machado; Nélio Gonçalves; Manuella P Kaster; Ana T Simões; Ana Nunes; Luís Pereira de Almeida; Ki Ann Goosens; Daniel Rial; Rodrigo A Cunha
Journal:  Neuropsychopharmacology       Date:  2016-06-17       Impact factor: 7.853

Review 5.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

Review 6.  Mouse models of spinocerebellar ataxia type 3 (Machado-Joseph disease).

Authors:  Veronica F Colomer Gould
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

7.  Overexpression of mutant ataxin-3 in mouse cerebellum induces ataxia and cerebellar neuropathology.

Authors:  Clévio Nóbrega; Isabel Nascimento-Ferreira; Isabel Onofre; David Albuquerque; Mariana Conceição; Nicole Déglon; Luís Pereira de Almeida
Journal:  Cerebellum       Date:  2013-08       Impact factor: 3.847

8.  Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.

Authors:  Erik Kvam; Brent L Nannenga; Min S Wang; Zongjian Jia; Michael R Sierks; Anne Messer
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

9.  Repeated Mesenchymal Stromal Cell Treatment Sustainably Alleviates Machado-Joseph Disease.

Authors:  Catarina Oliveira Miranda; Adriana Marcelo; Teresa Pereira Silva; João Barata; Ana Vasconcelos-Ferreira; Dina Pereira; Clévio Nóbrega; Sónia Duarte; Inês Barros; Joana Alves; José Sereno; Lorena Itatí Petrella; João Castelhano; Vitor Hugo Paiva; Paulo Rodrigues-Santos; Vera Alves; Isabel Nunes-Correia; Rui Jorge Nobre; Célia Gomes; Miguel Castelo-Branco; Luís Pereira de Almeida
Journal:  Mol Ther       Date:  2018-07-12       Impact factor: 11.454

10.  Nucleocytoplasmic shuttling activity of ataxin-3.

Authors:  Sandra Macedo-Ribeiro; Luísa Cortes; Patrícia Maciel; Ana Luísa Carvalho
Journal:  PLoS One       Date:  2009-06-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.